English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Goal of work: To compare the severity of oral mucositis, pain and xerostomia in head and neck cancer patients, who received radiotherapy with cisplatin and cetuximab to that of patients who received radiotherapy with cisplatin alone. Patients: Forty-nine head and neck cancer patients entered the study. Twenty-five patients (Group A) received radiotherapy and cisplatin. Twenty-four patients (Group B) received radiotherapy, cisplatin, and cetuximab. Methods: Oral mucositis was recorded weekly, according to EORTC/RTOG criteria. Pain and xerostomia were assessed using a 10cm visual analogue scale. Antifungal and antiviral treatment and prophylaxis were administered during RT to both groups. Results: During chemoradiotherapy, severe mucositis, pain and xerostomia were observed in 60%, 64% and 52% respectively in Group A, while the same symptoms were observed in 79%, 58% and 29% respectively in Group B. The differences between the two groups were not statistically significant. At the end of chemoradiotherapy, severe mucositis, pain and xerostomia were recorded in 24%, 32% and 32% in Group A and 37%, 21% and 17% respectively in Group B. The differences between the two groups were, again, statistically not significant. Neither significant differences were found between the two groups with respect to the use of antifungal and antiviral treatment, radiotherapy interruptions and weight loss. In both groups, oral mucositis, pain and xerostomia were significantly reduced at the end of radiotherapy as compared to those during RT, following the anti-infectious treatment and prophylaxis. Conclusion: Cetuximab, added to cisplatin/radiotherapy, did not increase the severity of oral mucositis, pain and xerostomia, in head and neck cancer patients, with limitations of the study design and its limited number of patients.

the open clinical cancer journal

Oral Mucositis, Pain and Xerostomia in Patients with Head and Neck Cancer who Received Chemoradiotherapy with or without Cetuximab~!2009-08-02~!2010-03-29~!2010-08-26~!